·PIB·15 marks·250–350 words

"Drug quality is not only made in the factory but also lost in the warehouse." Examine the significance of incorporating Good Storage and Distribution Practices into the Drugs Rules, 1945.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. How quality is lost after manufacture
  2. Significance of the amendment
  3. Challenges

Good Storage and Distribution Practices (GSDP) are standards that keep a medicine's quality, safety and efficacy intact from the manufacturer to the patient [1]. India has mostly regulated drug quality at the factory. The Health Ministry's proposal to put CDSCO's GSDP guidance into the Drugs Rules, 1945 extends that regulation to the supply chain [1].

How quality is lost after manufacture

  • Deterioration, contamination and mix-ups during storage and transport [1].
  • Falsification and diversion: fake drugs enter the chain and genuine ones leak out of authorised channels. WHO estimates that at least 1 in 10 medical products in low- and middle-income countries is substandard or falsified [2].
  • A Parliamentary Standing Committee estimated that 7–8% of drugs in India are not of standard quality (NSQ) and 0.5% are spurious [3].

Significance of the amendment

  • Legal force: guidance becomes a binding rule, which strengthens inspection by Central and State drug controllers [1].
  • Whole-chain accountability: it covers manufacturers, importers, wholesalers, distributors and stockists [1].
  • Traceability: records of procurement, storage and transport can show where quality was lost. At present, NSQ alerts and recalls are aimed at the manufacturer [4].
  • Global alignment: it follows WHO TRS 1025, Annex 7 [5], which helps the credibility of India's pharmaceutical exports.
  • Public health: it protects temperature-sensitive products such as vaccines, which matters for immunisation cold chains.

Challenges

  • Inspector shortage: the Mashelkar Committee found too few trained staff and uneven enforcement across States [3].
  • Factory-focused enforcement: risk-based drives inspected 905 manufacturing units and acted against 694 [4]. Warehouses were not their focus.
  • Compliance costs for small stockists, such as temperature control and record-keeping.
  • Coverage gaps: online pharmacies are not named explicitly, even though WHO identifies online sales as a growing route for falsified medicines [1][2].

GSDP closes the gap between a drug that is made right and a drug that reaches the patient right. Its success will depend on implementation: States should create inspector posts based on workload, as Mashelkar recommended [3]; regulators should sample at the wholesale level; compliance should be phased in for small stockists; and the Rules should state clearly whether e-pharmacies are covered. Done well, the reform supports Article 47 and SDG 3.8 by making sure the quality built in the factory is kept in the warehouse.

Sources

  1. 1Press Information Bureau – Health Ministry proposal to incorporate GSDP into the Drugs Rules, 1945 (19 Nov 2026)what GSDP is, its scope, the entities covered, the risks it targets, Centre–State enforcement, and the move from guidance to Rules
  2. 2WHO Fact Sheet – Substandard and falsified medical productsthe 1-in-10 estimate and online sales as a channel
  3. 3PRS Legislative Research – Demand for Grants 2018-19 Analysis: Health and Family WelfareNSQ/spurious estimates and Mashelkar Committee findings on staffing and State enforcement
  4. 4Press Information Bureau – Steps taken to prevent sale of adulterated drugs905 units inspected and 694 actions; NSQ drug alerts and manufacturer recalls
  5. 5WHO – TRS 1025, Annex 7: Good storage and distribution practices for medical productsthe global GSDP benchmark

More from this note